While many trials are still underway to evaluate the impact of checkpoint inhibitors on GBM, it was discovered that TMZ therapy can disrupt PD-L1 expression in recurrent GBM [90, 91], which may explain the negative results seen in trials evaluating nivolumab for recurrent GBM. The gene discussed is CD274; the disease is glioblastoma.